Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Raludotatug deruxtecan by Daiichi Sankyo for Ovarian Cancer: Likelihood of Approval
Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Ovarian Cancer. According to GlobalData,...
Raludotatug deruxtecan by Daiichi Sankyo for Peritoneal Cancer: Likelihood of Approval
Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Peritoneal Cancer. According to GlobalData,...
Raludotatug deruxtecan by Daiichi Sankyo for Fallopian Tube Cancer: Likelihood of Approval
Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Fallopian Tube Cancer. According to...